ANTIDEPRESSANT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Antidepressant Market, By Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIs) (Fluoxetine, Sertraline, and Others), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) (Venlafaxine, Duloxetine, and Others), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), and Atypical Antidepressants), By Route of Administration (Oral, Subcutaneous, Intravenous, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In August 2023, Biogen Inc. and Sage Therapeutics, Inc. announced that the FDA has approved ZURZUVAE (zuranolone) 50 mg for adults with postpartum depression. It is the first oral, once-daily, 14-day treatment for rapid relief from depressive symptoms in PPD. ZURZUVAE is expected to launch in Q4 2023, pending its scheduling as a controlled substance by the DEA.
On April 2024, Strides Pharma Science stated that its subsidiary, Strides Pharma Global Pte. Limited, has received FDA approval for Fluoxetine Tablets. This generic version is both bioequivalent and therapeutically equivalent to Eli Lilly's Prozac. Fluoxetine, an SSRI antidepressant, is used to treat major depressive disorder, OCD, bulimia nervosa, and panic disorder.
On May 2024, Johnson & Johnson announced positive topline results from the Phase 3 MDD3001 trial, which assessed seltorexant as an adjunctive treatment for major depressive disorder (MDD) with insomnia. Seltorexant, a first-in-class orexin-2 receptor antagonist, showed efficacy and safety in combination with baseline antidepressants for treating MDD with insomnia.